Dova Pharmaceuticals (DOVA) Misses Q3 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. BIIB
7. CMG
8. TENB
9. KLAC
10. ETSY

Go back to Dova Pharmaceuticals (DOVA) Misses Q3 EPS by 6c

Dova Pharmaceuticals Reports Third Quarter 2017 Operating and Financial Results

November 9, 2017 4:05 PM EST

NDA for avatrombopag submitted to FDA

Conference call scheduled for 4:30 p.m. EST today

DURHAM, N.C., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today reported its operating and financial results for the quarter ended September 30, 2017.

Third Quarter and Recent Highlights

Submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Dova's drug candidate, avatrombopag, for the treatment of thrombocytopenia in... More